BMRN vs RGNX
BMRN: BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene therapies with a proven $3.2 billion commercial franchise. RGNX: Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with major pharma.
Side-by-side fundamentals
| Metric | BMRN | RGNX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $60.27 | $10.12 | |
| Market cap as of 2026-07-31 | $11.7B | $523M | |
| P/E as of 2026-07-31 | 43.48 | n/a | |
| PEG as of 2026-07-31 | n/a | -0.02 | |
| Net margin as of 2026-07-31 | +8.3% | -330.2% | BMRN higher |
| Gross margin as of 2026-07-31 | +80.2% | +68.2% | BMRN higher |
| Operating margin as of 2026-07-31 | +9.7% | -292.3% | BMRN higher |
| ROE as of 2026-07-31 | +4.4% | -232.5% | BMRN higher |
| ROA as of 2026-07-31 | +3.4% | -61.0% | BMRN higher |
| Debt / equity as of 2026-07-31 | 0.23 | 8.41 | BMRN lower |
| Revenue growth (YoY) as of 2026-07-31 | +9.9% | -44.0% | BMRN higher |
| Revenue CAGR (3y) SEC XBRL | +15.4% | +14.8% | BMRN higher |
| Beta as of 2026-07-31 | 0.21 | 1.84 | |
| 1-year return as of 2026-07-27 close | +2.1% | +15.7% | RGNX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.